Nicox’s NCX 470 Hits Phase III Endpoint In Glaucoma But Misses Superiority

NCX 470 demonstrates non-inferiority in intraocular pressure reduction versus latanoprost in the first of two Phase III studies, but does not meet a secondary endpoint that would have shown superiority.